clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with clarithromycin
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Furusyo N et al. | Rapidly growing primary gastric B-cell lymphoma after eradication of Helicobacter pylori. | 1999 | Intern. Med. | pmid:10526942 |
Chérin P et al. | Macrophagic myofasciitis: improvement with antibiotic therapy. | 1999 | J. Rheumatol. | pmid:10529163 |
Moola S et al. | A multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia. | 1999 | Chest | pmid:10531162 |
Gonzalez Cueto D et al. | [Gastric solitary plasmacytoma associated with +Helicobacter pylori infection]. | 1999 | Acta Gastroenterol. Latinoam. | pmid:10533659 |
Saito H et al. | [Chemoprophylaxis against Mycobacterium avium complex infection induced in mice]. | 1999 | Kekkaku | pmid:10535281 |
Gisbert JP et al. | Seven-day 'rescue' therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole. | 1999 | Aliment. Pharmacol. Ther. | pmid:10540045 |
Hammett DC and Evans MF | Functional (non-ulcer) dyspepsia and Helicobacter pylori infection. To treat or not to treat? | 1999 | Can Fam Physician | pmid:10540692 |
Sassa K et al. | Differential modulatory effects of clarithromycin on the production of cytokines by a tumor. | 1999 | Antimicrob. Agents Chemother. | pmid:10543765 |
Goldstein EJ et al. | Activities of telithromycin (HMR 3647, RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and other antimicrobial agents against unusual anaerobes. | 1999 | Antimicrob. Agents Chemother. | pmid:10543769 |
Unal M et al. | Ocular toxicity of intravitreal clarithromycin. | 1999 | Retina (Philadelphia, Pa.) | pmid:10546942 |
Woo PC et al. | Antibiotics modulate vaccine-induced humoral immune response. | 1999 | Clin. Diagn. Lab. Immunol. | pmid:10548572 |
Adamsson I et al. | Comparative effects of omeprazole, amoxycillin plus metronidazole versus omeprazole, clarithromycin plus metronidazole on the oral, gastric and intestinal microflora in Helicobacter pylori-infected patients. | 1999 | J. Antimicrob. Chemother. | pmid:10552979 |
Cirioni O et al. | In-vitro activity of rifabutin and albendazole singly and in combination with other clinically used antimicrobial agents against Pneumocystis carinii. | 1999 | J. Antimicrob. Chemother. | pmid:10552982 |
Yoshida Y et al. | Synthesis and anti-Helicobacter pylori activity of FR182024, a new cephem derivative. | 1999 | Bioorg. Med. Chem. Lett. | pmid:10560737 |
Valencia IC et al. | Disseminated cutaneous Mycobacterium chelonae infection after injection of bovine embryonic cells. | 1999 | Int. J. Dermatol. | pmid:10561050 |
MartÃn de Argila C and Boixeda D | [A ration proposal for the eradicating treatment of Helicobacter pylori infection]. | 1999 | Med Clin (Barc) | pmid:10562929 |
Adeyemi EO et al. | The outcome of a 2-week treatment of Helicobacter pylori-positive duodenal ulcer with omeprazole-based antibiotic regimen in a region with high metronidazole resistance rate. | 1999 | Eur J Gastroenterol Hepatol | pmid:10563537 |
Sharma VK et al. | A survey of gastroenterologists' perceptions and practices related to Helicobacter pylori infection. | 1999 | Am. J. Gastroenterol. | pmid:10566709 |
Fattorini L et al. | Activities of eighteen antimicrobial regimens against Mycobacterium avium infection in beige mice. | 1999 | Microb. Drug Resist. | pmid:10566874 |
Lamouliatte H et al. | Double vs. single dose of pantoprazole in combination with clarithromycin and amoxycillin for 7 days, in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. | 1999 | Aliment. Pharmacol. Ther. | pmid:10571611 |
Stengel W | [Sporotrichoid mycobacteriosis caused by Mycobacterium marinum]. | 1999 | Dtsch. Med. Wochenschr. | pmid:10572519 |
Madsen LG et al. | Ménétrier's disease and Helicobacter pylori: normalization of gastrointestinal protein loss after eradication therapy. | 1999 | Dig. Dis. Sci. | pmid:10573379 |
Mach T and Zahradnik-Bilska J | [Reinfection with Helicobacter pylori in patients with duodenal ulcer after successful eradication]. | 1999 | Prz. Lek. | pmid:10575912 |
Dionisio D et al. | Encephalitis caused directly by Mycoplasma pneumoniae. | 1999 | Scand. J. Infect. Dis. | pmid:10576133 |
Huchon G | How to manage the low-risk patient with lower respiratory tract infection? | 1999 | Respiration | pmid:10577170 |
de Luis DA et al. | Improvement in lipid and haemostasis patterns after Helicobacter pylori infection eradication in type 1 diabetic patients. | 1999 | Clin Nutr | pmid:10578022 |
Tanigawara Y et al. | CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. | 1999 | Clin. Pharmacol. Ther. | pmid:10579481 |
Tomioka H et al. | Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. | 1999 | Antimicrob. Agents Chemother. | pmid:10582897 |
Komatsu H et al. | Mycobacterium avium infection of the skin associated with lichen scrofulosorum: report of three cases. | 1999 | Br. J. Dermatol. | pmid:10583068 |
Semret M et al. | Mycobacterium ulcerans infection (Buruli ulcer): first reported case in a traveler. | 1999 | Am. J. Trop. Med. Hyg. | pmid:10586895 |
Nasu T et al. | [In vitro antibacterial activity of faropenem, a novel oral penem antibiotic, against enterohemorrhagic Escherichia coli O157 strains]. | 1999 | Jpn J Antibiot | pmid:10587879 |
Langan CE et al. | Randomized, double-blind study of short-course (5 day) grepafloxacin versus 10 day clarithromycin in patients with acute bacterial exacerbations of chronic bronchitis. | 1999 | J. Antimicrob. Chemother. | pmid:10588313 |
Rodvold KA | Clinical pharmacokinetics of clarithromycin. | 1999 | Clin Pharmacokinet | pmid:10589373 |
Franzin L et al. | Clarithromycin and amoxicillin susceptibility of Helicobacter pylori strains isolated from adult patients with gastric or duodenal ulcer in Italy. | 2000 | Curr. Microbiol. | pmid:10594221 |
Dani R et al. | Omeprazole, clarithromycin and furazolidone for the eradication of Helicobacter pylori in patients with duodenal ulcer. | 1999 | Aliment. Pharmacol. Ther. | pmid:10594400 |
Harris A | The importance of clarithromycin dose in the management of H. pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. | 1999 | Aliment. Pharmacol. Ther. | pmid:10594406 |
Gomollón F et al. | Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton-pump inhibitor-based therapy: a detailed, prospective analysis of 21 consecutive cases. | 1999 | Helicobacter | pmid:10597390 |
Uygun A et al. | The effect of Helicobacter pylori eradication on duodenal gastric metaplasia. | 1999 Jul-Aug | J. Int. Med. Res. | pmid:10599027 |
Auclair B et al. | Potential interaction between itraconazole and clarithromycin. | 1999 | Pharmacotherapy | pmid:10600094 |
Feldman M et al. | Influence of H. pylori infection on meal-stimulated gastric acid secretion and gastroesophageal acid reflux. | 1999 | Am. J. Physiol. | pmid:10600812 |
Raderer M et al. | Regression of colonic low grade B cell lymphoma of the mucosa associated lymphoid tissue type after eradication of Helicobacter pylori. | 2000 | Gut | pmid:10601069 |
Sainz R et al. | [Helicobacter pylori infection. The Spanish consensus report. The Spanish Consensus Conference Group]. | 1999 | Rev Esp Enferm Dig | pmid:10601771 |
Tanaka G et al. | Effect of clarithromycin on Pseudomonas aeruginosa biofilms. | 2000 Jan-Feb | Chemotherapy | pmid:10601796 |
Hamada K et al. | Adjuvant effect of clarithromycin on chemotherapy for murine lung cancer. | 2000 Jan-Feb | Chemotherapy | pmid:10601798 |
Fernández-Roblas R et al. | In vitro susceptibilities of rapidly growing mycobacteria to telithromycin (HMR 3647) and seven other antimicrobials. | 2000 | Antimicrob. Agents Chemother. | pmid:10602744 |
Ku YY et al. | Synthesis and antibacterial activities of novel 12-O-methylerythromycin A derivatives. | 1999 | J. Antibiot. | pmid:10604761 |
Ianaro A et al. | Anti-inflammatory activity of macrolide antibiotics. | 2000 | J. Pharmacol. Exp. Ther. | pmid:10604943 |
Suzuki K et al. | Effect of proton pump inhibitor alone or in combination with clarithromycin on mycobacterial growth in human alveolar macrophages. | 2000 | FEMS Microbiol. Lett. | pmid:10612733 |
Giacometti A et al. | In vitro anticryptosporidial activity of ranalexin alone and in combination with other peptides and with hydrophobic antibiotics. | 1999 | Eur. J. Clin. Microbiol. Infect. Dis. | pmid:10614961 |
Midolo PD et al. | In vitro synergy between ranitidine bismuth citrate and tetracycline or clarithromycin against resistant strains of Helicobacter pylori. | 1999 | Eur. J. Clin. Microbiol. Infect. Dis. | pmid:10614963 |